Search

Now showing items 1-10 of 34

Lenalidomide Enhances Human Alloresponses By Increasing Proliferation of Effector Memory CD8 T Cells with Enhanced Polyfunctional Effector Capacity and a Unique Gene Expression Profile

Besley, CM; Kotsiou, E; Petty, R; Sangaralingum, A; Le Dieu, R; Gribben, JG; Davies, JK (2014-12-06)

Oxidative stress downstream of mTORC1 but not AKT causes a proliferative defect in cancer cells resistant to PI3K inhibition

Dermit, M; Casado, P; Rajeeve, V; Wilkes, EH; Foxler, DE; Campbell, H; Critchlow, S; Sharp, TV; Gribben, JG; Unwin, R;... (2017-05-11)

CD160 signaling mediates PI3K-dependent survival and growth signals in chronic lymphocytic leukemia

Liu, FT; Giustiniani, J; Farren, T; Jia, L; Bensussan, A; Gribben, JG; Agrawal, SG (2010-04-15)

Enhanced activation of an amino-terminally truncated isoform of the voltage-gated proton channel HVCN1 enriched in malignant B cells

Hondares, E; Brown, MA; Musset, B; Morgan, D; Cherny, VV; Taubert, C; Bhamrah, MK; Coe, D; Marelli-Berg, F; Gribben, JG;... (2014-12-16)

Hit-and-run epigenetic editing prevents senescence entry in primary breast cells from healthy donors.

Saunderson, EA; Stepper, P; Gomm, JJ; Hoa, L; Morgan, A; Allen, MD; Jones, JL; Gribben, JG; Jurkowski, TP; Ficz, G (2017-11-13)

Aberrant promoter DNA hypermethylation is a hallmark of cancer; however, whether this is sufficient to drive cellular transformation is not clear. To investigate this question, we use a CRISPR-dCas9 epigenetic editing tool, ...

Randomized phase 3 study of lenalidomide versus chlorambucil as first-line therapy for older patients with chronic lymphocytic leukemia (the ORIGIN trial)

Chanan-Khan, A; Egyed, M; Robak, T; Martinelli de Oliveira, FA; Echeveste, MA; Dolan, S; Desjardins, P; Blonski, JZ; Mei, J; Golany, N;... (2017-05)

Search

Lenalidomide Enhances Human Alloresponses By Increasing Proliferation of Effector Memory CD8 T Cells with Enhanced Polyfunctional Effector Capacity and a Unique Gene Expression Profile

Oxidative stress downstream of mTORC1 but not AKT causes a proliferative defect in cancer cells resistant to PI3K inhibition

CD160 signaling mediates PI3K-dependent survival and growth signals in chronic lymphocytic leukemia

Enhanced activation of an amino-terminally truncated isoform of the voltage-gated proton channel HVCN1 enriched in malignant B cells

Hit-and-run epigenetic editing prevents senescence entry in primary breast cells from healthy donors.

Randomized phase 3 study of lenalidomide versus chlorambucil as first-line therapy for older patients with chronic lymphocytic leukemia (the ORIGIN trial)

Genomic profiling reveals spatial intra-tumor heterogeneity in follicular lymphoma

Endothelial-cell FAK targeting sensitizes tumours to DNA-damaging therapy

TNFRSF14 aberrations in follicular lymphoma increase clinically significant allogeneic T-cell responses

Generation of Functional CLL-Specific Cord Blood CTL Using CD40-Ligated CLL APC

Search

Filters

Lenalidomide Enhances Human Alloresponses By Increasing Proliferation of Effector Memory CD8 T Cells with Enhanced Polyfunctional Effector Capacity and a Unique Gene Expression Profile

Oxidative stress downstream of mTORC1 but not AKT causes a proliferative defect in cancer cells resistant to PI3K inhibition

CD160 signaling mediates PI3K-dependent survival and growth signals in chronic lymphocytic leukemia

Enhanced activation of an amino-terminally truncated isoform of the voltage-gated proton channel HVCN1 enriched in malignant B cells

Hit-and-run epigenetic editing prevents senescence entry in primary breast cells from healthy donors.

Randomized phase 3 study of lenalidomide versus chlorambucil as first-line therapy for older patients with chronic lymphocytic leukemia (the ORIGIN trial)

Genomic profiling reveals spatial intra-tumor heterogeneity in follicular lymphoma

Endothelial-cell FAK targeting sensitizes tumours to DNA-damaging therapy

TNFRSF14 aberrations in follicular lymphoma increase clinically significant allogeneic T-cell responses

Generation of Functional CLL-Specific Cord Blood CTL Using CD40-Ligated CLL APC